How to manage bridging therapies prior to CAR T cells in multiple myeloma?

During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?

Einsele begins by explaining why bridging therapy is important in patients with multiple myeloma with a high tumor load. This is followed by a discussion on what should be considered when choosing a bridging therapy regimen, such as the incidence of cytopenias and infection risk.